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Objective To study the influence of soluble tumour necrosis factor (TNF) receptors (sTNFR) on bioactivity
and immunoreactivity of TNF-a in patients with visceral leishmaniasis (Kala-azar) and to examine the association
between circulating levels of sTNFR type I and type II with clinical manifestations of the disease.
Methods Ten patients with Kala-azar were enrolled. Plasma samples for TNF-a and sTNFR were obtained
on days 0, 7 and 21–28 of antimonial therapy. Bioactivity of TNF-a was measured by cytotoxicity to L-929
cells and immunoreactivity by enzyme-linked immunosorbent assay (ELISA). sTNFR-I and sTNFR-II were
measured by ELISA.
Results Measured by ELISA, TNF-a was detected at baseline in all patients (range from 22.3 to 163 pg/mL)
and showed a linear decline over time on therapy (r = 0.49, P = 0.007). In contrast, when measured by
cytotoxicity assay, TNF-a was detected in only one patient at baseline (193 pg/mL) and in four patients at the
end of therapy (38.7, 95, 133 and 232 pg/mL) and there was no linear association between TNF-a and duration
of therapy (r = 0.18, P = 0.45). sTNFR-I and sTNFR-II were detected in all patients before therapy. There
was a strong positive correlation between plasma concentrations of sTNFR-I and sTNFR-II (r = 0.8, P = 0.006).
Levels of sTNFR-I and sTNFR-II declined exponentially with time on therapy.
Conclusions We concluded that sTNFR-I and sTNFR-II are related to disease activity in patients with Kala-
azar and that these circulating receptors may interfere with the biological activity of TNF-a in patients with
Kala-azar.
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INTRODUCTION
Leishmaniasis is prevalent in tropical and subtropical areas. In
1990, the World Health Organization estimated that 350
million people had became infected and 12 million had
developed the disease [1]. A wide spectrum of clinical mani-
festations are seen in leishmaniasis, which are related to the
Leishmania species and the immune status of the infected host.
Evidence from experimental cutaneous leishmaniasis suggests
a protective role for TNF-a. This cytokine has been shown to
be produced in the lymph nodes of a resistant strain (C3H) of
mice infected with Leishmania major, whereas no such
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production is observed in susceptible mice (Balb/c) [2]. Admin-
istration of recombinant TNF-a to susceptible mice causes a
reduction in cutaneous lesions, whereas administration of anti-
TNF-a antibodies causes progression of lesions [2,3]. In exper-
imental visceral leishmaniasis TNF-a seems to be critical both
for resistance to Leishmania donovani and resolution of infection
[4].
Evaluation of the role of TNF-a in patients with Kala-azar
has drawn increasing interest. Patients with visceral leish-
maniasis often present with weakness, weight loss, and anaemia;
symptoms that could be mediated by TNF-a [5]. Circulating
TNF-a has been detected in patients with visceral leishmaniasis
[6,7] and its presence has been related to disease activity [8,9].
Although the levels of TNF-a measured by immuno-
reactivity decline with therapy, TNF-a measured by cyto-
toxicity assay, and thus bioactive TNF, has an unpredictable
course [9]. Biological activity of TNF-a is transduced by two
receptors, of 55 and 75 kDa molecular weight [10,11], which
mediate distinct cellular responses [12]. The release of the extra-
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cellular domains of TNF receptors from cell surfaces, i.e. soluble
TNF receptors (sTNFR), is observed in a wide range of
inflammatory and infectious diseases. These soluble receptors
may be functionally active as TNF-neutralizing proteins [13–
15], or they may prolong the stability of TNF bioactivity in the
serum [16].
The main objectives of the present work were: (1) to examine
the association between circulating levels of sTNFR type I and
type II (sTNFR-I and sTNFR-II) and clinical manifestations
of visceral leishmaniasis; and (2) to study the influence of the
presence of sTNFRs in the immunoactivity and bioactivity of
circulating TNF-a, measured by enzyme-linked immuno-
sorbent assay (ELISA) and by a cytotoxicity assay, respectively.
MATERIALS AND METHODS
Patients
We evaluated 10 patients with visceral leishmaniasis between
August 1995 and February 1996, admitted to an urban Brazilian
hospital (Giselda Trigueiro Hospital, Natal, North-east, Brazil).
Cases were diagnosed based on clinical manifestations, and
confirmed by the finding of Leishmania parasites in bone mar-
row and/or spleen aspirates. After obtaining informed consent,
each case underwent daily clinical evaluation and routine lab-
oratory work-up during hospitalization. All patients were tre-
ated with meglumine antimoniate.
Blood samples for TNF-a and sTNFR-I and sTNFR-II
were collected in heparinized tubes on days 0, 7 and 21–28 of
antimonial therapy. After separation, plasma was kept frozen at
70 °C in aliquots of 200–300 mL and thawed just before use.
Assay for TNF-a
Biological activity of TNF-a was measured by cytotoxicity to
L-929 cells and immunoreactivity was measured by ELISA
using the following methods.
Cytotoxicity assay was performed using sensitive L-929 cells
and human recombinant TNF-a (Genzyme, Cambridge, MA,
USA). Samples were tested in triplicate and in four dilutions.
One unit was defined as the amount of TNF-a able to induce
50% cell lysis. Sample dilution and concentration of human
recombinant TNF-a (hu r TNF-a; Genzyme) corresponding
to 50% cell lysis, was calculated by linear regression analysis.
Values expressed in units/mL were then converted to pg/mL
using a reference curve obtained with hu r TNF-a in each
assay. All samples from the same patient were tested in the same
assay. One unit of TNF-a (50% cell lysis) corresponded to
16.9 pg/mL (22.9 pg/mL).
For the ELISA, a commercially available kit was used (Gen-
zyme) and the test was performed following the manufacturer’s
instructions. Plasma samples and hu r TNF-a were tested in
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duplicate. The sensitivity of the test was 10 pg/mL. Accordingly
to the manufacturer, the detection of TNF-a is not affected by
the presence of 105 pg/mL of sTNFR (Genzyme).
Assay for sTNFR-I/R-II
sTNFR-I and sTNFR-II were measured by ELISA using a
commercially available Kit (R & D Quantikine Kits, Minne-
apolis, MN, USA) and following manufacturer’s instructions.
Statistical analyses
The changes in TNF-a levels during therapy were analysed
using linear regression analysis (Yi = b0 + b1xi), whereas the
changes of sTNFR-I and sTNFR-II over time were better
predicted by the model Yi = b0 e
b1xi, where xi is day of treat-
ment of the ith patient. The Mann–Whitney test was used to
compare baseline and end-of-therapy levels of TNF-a, and the
Wilcoxon test to compare sTNFR-I and sTNFR-II at baseline.
All analyses consisted of two-tailed tests, with an a level of 0.05.
Statistical programs 2D, 3D, 6D, and 1R of BMDP Statistical
Software Inc (University of California, 1992, Los Angeles, Cal-
ifornia, USA) were used.
RESULTS
Low fever, hepatomegaly, splenomegaly, anemia, leucopenia,
and hypoalbuminemia were common in our cases. All patients
were available for evaluation at 6 and 12 months after treatment
and all were asymptomatic.
Plasma levels of TNF-a were determined by ELISA and
cytotoxicity assays. When measured by ELISA, TNF-a was
detected at baseline in all patients (range from 22.3 to
163 pg/mL). The mean pretreatment plasma level of TNF-a
(62.7 2 40.6 pg/mL) was significantly higher than the mean
level at the end of therapy (13.4 2 32.9 pg/mL) (P = 0.01). In
addition, TNF-a levels showed a linear decline over time (r =
Figure 1 Correlation of sTNFR-I and sTNFR-II plasma concentrations
in patients with visceral leishmaniasis.
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Figure 2 Concentrations of sTNFR-I (a) and sTNFR-II (b) in patients
with visceral leishmaniasis before, during and after antimony
therapy.
0.49, P = 0.007). In contrast when measured by cytotoxicity
assay, TNF-a was detected in only one patient at baseline
(193 pg/mL) and in four patients at the end of therapy (38.7,
95, 133 and 232 pg/mL) and there was no linear association
between TNF-a and duration of therapy (r = 0.18, P = 0.45).
STNFR-I and sTNFR-II were detected in all patients before
therapy. Although baseline circulating levels of sTNFR-II
(range: 11 783–16 930 pg/mL; mean, 14 119 pg/mL) were sig-
nificantly higher than sTNFR-I (range 2867–7942 pg/mL;
mean, 4144 pg/mL) (P = 0.002), there was a strong positive
correlation between plasma concentrations of sTNFR-I and
sTNFR-II (r = 0.8, P = 0.006) (Figure 1). Levels of sTNFR-II
(range 3732–10993 pg/mL; mean, 6601 pg/mL) at the end of
therapy were significantly lower than baseline levels (P = 0.001)
and showed an exponential decline over time spent on therapy
(Yi = 13523 e
0.035xi; r = 0.54, P = 0.02). Similarly, sTNFR-I
levels were significantly lower at the end of therapy (range:
740–2606 pg/mL; mean, 1516 pg/mL) and also declined expo-
nentially with time (Yi = 3649 e
0.0487xi; r = 0.64, P  0.001)
(Figures 2a,b).
DISCUSSION
Our results show that sTNFR-I and sTNFR-II are detectable
during visceral leishmaniasis activity and that their levels decline
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with antimony therapy and clinical recovery, a finding that is
in agreement with a previous report [17].
As previously suggested [17], detection of sTNFR-I and
sTNFR-II, similar to circulating levels of immunoreactive
TNF-a [8,9], soluble interleukin (SIL)-2R [18], and IL-10 [19],
is related to disease activity in patients with Kala-azar. The
possible role that these receptors may play in neutralizing the
bioactivity of TNF-a is also important. These receptors protect
cells from TNF toxicity. Interestingly, sTNFR-I and sTNFR-
II can independently and completely displace the binding of
TNF-a and inhibit its cytotoxicity [15]. Thus the release of
sTNFR is thought to be a natural inhibitory mechanism in
response to TNF-a activity. To investigate this point we
measured the circulating levels of TNF-a by ELISA and by
cytotoxicity to L-929 cells. A striking discrepancy was observed.
TNF-a was detected by ELISA in all patients before therapy,
and in only one patient by cytotoxicity. This discrepancy may
at least in part be due to the presence of sTNFR. Aukrust et al.
[20] reported different results on detection of serum levels of
TNF-a in patients infected by the human immunodeficiency
virus (HIV) measured by ELISA and cytotoxicity (100 and 27%
positivity, respectively). They attributed this discrepancy to the
presence of high levels of TNF-a circulating receptor (TNFR)
in these patients. It has been demonstrated that detection of
TNF-a in presence of sTNFR is dependent on the assay used
[21]. Engelberts et al. [21] reported that detection was not alt-
ered by radioimmunoassay, was partially decreased by ELISA,
and greatly impaired by cytotoxicity assay. In autoimmune
diseases [13,22] it has been shown that sera of patients con-
taining sTNFR abrogate the cytotoxicity of recombinant TNF-
a. Furthermore, addition of sTNFR-I and sTNFR-II neu-
tralizes endogenous TNF-a cytotoxicity induced by lipo-
polysaccharide (LPS) [14].
We also found a positive correlation between sTNFR-I and
sTNFR-II levels at baseline and that both decline in a similar
fashion during therapy, although sTNFR-II was detected at
higher levels. A positive correlation between sTNFR-I and
sTNFR-II has consistently been shown in experimental
inflammatory and autoimmune diseases [13–15]. This suggests
that the induction of both types of sTNFR occurs in a coregu-
lated fashion in these diseases [13]. This is interesting, since it
has been shown that TNFR-I and TNFR-II are differentially
expressed on different cell lines [10,11] and that the synthesis
of the two types of receptors is independently regulated [23,24].
The source of these proteins in visceral leishmaniasis is
unknown. It has been suggested that in rheumatoid arthritis
these proteins reflect the state of activation of poly-
morphonuclear cells and lymphocyte activation [22].
As the circulating levels of sTNFR decline, TNF-a cyto-
toxicity is detected at least in some of our patients, which further
suggests that sTNFR is associated with lack of cytotoxicity on
baseline samples. Our data suggests that the TNF-a measured by
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immunoassay in visceral leishmaniasis may not be biologically
active. This would have a beneficial effect by protecting the host
from chronic exposure to TNF-a. Indeed, although circulating
levels have been described in many reports, the acute effects of
TNF-a, such as hypotension and intravascular coagulation, are
not seen in patients with visceral leishmaniasis, except when
complicated by bacterial infections. On the other hand the
presence of sTNFR could be a mechanism whereby the parasite
evades its toxicity, which may contribute to the lack of mac-
rophage activation seen in these patients.
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